0000000000394198

AUTHOR

Stefano Meletti

showing 4 related works from this author

Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis

2023

Background and ObjectivesUncontrolled evidence suggests that autologous hematopoietic stem cell transplantation (AHSCT) can be effective in people with active secondary progressive multiple sclerosis (SPMS). In this study, we compared the effect of AHSCT with that of other anti-inflammatory disease-modifying therapies (DMTs) on long-term disability worsening in active SPMS.MethodsWe collected data from the Italian Bone Marrow Transplantation Study Group and the Italian Multiple Sclerosis Register. Patients were considered eligible if treatment had been started after the diagnosis of SPMS. Disability worsening was assessed by the cumulative proportion of patients with a 6-month confirmed dis…

Hematopoietic Stem Cell TransplantationActive Secondary Progressive Multiple SclerosisNeurology (clinical)Research Article
researchProduct

Reduced Admissions for Cerebrovascular Events during COVID-19 Outbreak in Italy

2020

Supplemental Digital Content is available in the text.

disease outbreakMalemedicine.medical_treatment030204 cardiovascular system & hematologyItaly; cerebral hemorrhage; disease outbreaks; incidence; ischemic attack transient0302 clinical medicineEpidemiology80 and overMedicineischemic attack transientThrombolytic Therapy10178Acute ischemic stroke10177ThrombectomyAged 80 and overIschemic AttackTransientIncidence (epidemiology)Endovascular ProceduresMiddle AgedHospitalization1006210183ItalyComputingMethodologies_DOCUMENTANDTEXTPROCESSINGSettore MED/26 - NeurologiaFemaleCardiology and Cardiovascular Medicinecerebral hemorrhage; disease outbreaks; incidence; ischemic attack transient; Italy; Aged; Aged 80 and over; COVID-19; Cerebral Hemorrhage; Endovascular Procedures; Female; Hospitalization; Humans; Ischemic Attack Transient; Ischemic Stroke; Italy; Male; Middle Aged; Thrombectomy; Thrombolytic Therapymedicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)RevascularizationSettore MED/261015203 medical and health sciencesHumansAgedIschemic StrokeAdvanced and Specialized Nursingcerebral hemorrhagebusiness.industryOutbreakCOVID-19Emergency medicinedisease outbreaksincidenceBrief ReportsNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Do neurologists agree in diagnosing drug resistance in adults with focal epilepsy?

2019

Objective: To evaluate interrater agreement in categorizing treatment outcomes and drug responsiveness status according to the International League Against Epilepsy (ILAE) definition of drug-resistant epilepsy. Methods: A total of 1053 adults with focal epilepsy considered by the investigators to meet ILAE criteria for drug resistance were enrolled consecutively at 43 centers and followed up prospectively for 18-34 months. Treatment outcomes for all antiepileptic drugs (AEDs) used up to enrollment (retrospective assessment), and on an AED newly introduced at enrollment, were categorized by individual investigators and by 2 rotating members of a 16-member expert panel (EP) that reviewed the …

AdultMale0301 basic medicineDrug Resistant Epilepsymedicine.medical_specialtyPediatricsNeurologyAttitude of Health PersonnelTreatment outcomeantiepileptic drugs; classification; drug-resistant epilepsy; epilepsy; ILAE definition; reliability; Neurology; Neurology (clinical)Drug resistance03 medical and health sciencesEpilepsyantiepileptic drug0302 clinical medicinedrug-resistant epilepsymedicineHumansNeurologistsProspective Studiesantiepileptic drugsCooperative Behaviorreliabilitybusiness.industryMiddle Agedmedicine.diseaseDrug Resistant EpilepsyConfidence intervalInter-rater reliability030104 developmental biologyclassificationNeurologyepilepsyAnticonvulsantsFemaleEpilepsies PartialNeurology (clinical)businessILAE definition030217 neurology & neurosurgeryKappa
researchProduct

Brivaracetam as add-on treatment in patients with post-stroke epilepsy: real-world data from the BRIVAracetam add-on First Italian netwoRk Study (BRI…

2022

Objective: Post-stroke epilepsy (PSE) is one of the most common causes of acquired epilepsy and accounts for about 10-15% of all newly diagnosed epilepsy cases. However, evidence about the clinical profile of antiseizure medications in the PSE setting is currently limited. Brivaracetam (BRV) is a rationally developed compound characterized by high-affinity binding to synaptic vesicle protein 2A. The aim of this study was to assess the 12-month effectiveness and tolerability of adjunctive BRV in patients with PSE treated in a real-world setting. Methods: This was a subgroup analysis of patients with PSE included in the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST). The BRIVAFI…

AdultAntiseizure medication; Brivaracetam; Cerebrovascular diseases; Focal seizures; StrokeCerebrovascular diseasesSettore MED/26Antiseizure medication Brivaracetam Focal seizures Stroke Cerebrovascular diseasesFocal seizuresDouble-Blind MethodDrug TherapySeizuresHumansAgedRetrospective StudiesAntiseizure medicationEpilepsyGeneral MedicineMiddle AgedPyrrolidinonesStrokeTreatment OutcomeNeurologyItalyCombinationBrivaracetamAntiseizure medication; Brivaracetam; Cerebrovascular diseases; Focal seizures; Stroke; Adult; Aged; Anticonvulsants; Double-Blind Method; Drug Therapy Combination; Humans; Italy; Middle Aged; Pyrrolidinones; Retrospective Studies; Seizures; Treatment Outcome; Epilepsy; StrokeDrug Therapy CombinationAnticonvulsantsNeurology (clinical)
researchProduct